Nomination for 2018 CABS K. Fong Award in Life Sciences
Date: February 21, 2018 @ 12:00 am – June 23, 2018
Location: online
Nomination for 2018 CABS K. Fong Award in Life Sciences
CABS K. Fong Award in Life Sciences is presented annually to recognize those individuals who make significant contributions in life sciences and biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life.
Candidates must be nominated by an active member of CABS. Selection criteria will be based on candidate’s accomplishments in life sciences and contribution to the life science community, including one or all of the following:
· Proven achievements in therapeutic breakthroughs (including discovery, process or clinical development), diagnostics or the research reagent/equipment markets.
· Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications.
· Significant contribution to the CABS community and to promoting international collaboration in life sciences.
Winners will be selected by the CABS Award Selection Committee. The winner(s) will receive a Plaque of Merit at the Annual CABS Conference (BioPacific Conference) on June 23, 2018.
Please click the following link to nominate your candidate for the 2017 CABS K. Fong Award in Life Sciences: http://links.cabsweb.org/cabs-k-fong-award-nomination/
About Dr. Kenneth Fong
Dr. Kenneth Fong is a successful entrepreneur, an investor and mentor to many biotech founders, a community leader supporting higher education and a philanthropist. Currently Dr. Fong is the Chairman of Kenson Ventures, LLC, a venture capital firm that specializes in venture financing and strategic consulting to biotech companies. He is the founder and former CEO of Clontech, which developed and marketed Molecular Biology products to academic and pharmaceutical laboratories in the US and thirty other countries. He sits on the Boards of numerous biotech companies and serves on the advisory board of biotech-related entities in the US, China, Taiwan and Hong Kong.
Dr. Fong is active with both philanthropic and community activities. For example, he and his wife were major contributors in establishing the Fong Optometry and Medical Library at UC Berkeley, the Fong Scholarship Programs / Annual Scientific Symposia at San Francisco State University, the Annual Fong-Clontech Seminar series at Indiana University. His Community services included Chairman of the San Jose Chinese Performing Arts Center (2000-02), lead supporter to the Chinese Historical Society of America (SF, 2000) and the pioneering Biotech Program at the San Jose Tech Museum (1999). Recently, he has become more supportive of the educational programs for children in under-served and impoverished regions of China. He is a member of Committee 100 and a former member of the Board of 80-20 Initiative.
Currently Ken spends a good amount of time cultivating and advising a number of entrepreneurs (40-55 years old group) to grow their biotech companies.
Past recipients of CABS K. Fong Awards
2017: Dr. Yinxiang Wang, Co-founder and CSO of Beta Pharma, for his role in leading development and commercialization of Conmana®, the first small molecule oncology drug specifically targeting cancer cells that is completely developed in China, and Dr. Edgar Engleman, for his pioneering research that was the basis of the Sipuleucel-T (Provenge) prostate cancer vaccine, the first active immunotherapy for cancer to be approved by the FDA.
2016: Dr. Gerald Chen, Co-founder of Morningside, for his extraordinary vision and leadership in cultivating a generation of successful entrepreneurs and life sciences companies.
2015: Dr. Irving Weissman, of Stanford University, for his pioneering research in stem cell research.
2014: Dr. Ge Li, Founder and CEO of Wuxi Apptec, for creating and shaping the CRO business model in China and Dr. Hing L. Sham, formerly of Abbott for his leading role in the discovery of life- saving HIV protease inhibitors, ritonavir and Iopinavir.
2013: Dr. Peter Hirth, Plexxikon & Sugen for his pivotal role in advancing 4 successful drugs to the market and Dr. Jean Cui, formerly of Pfizer for her role as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.
.